OncoMatch/Clinical Trials/NCT05873686
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Is NCT05873686 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies NXP900 for advanced solid tumor.
Treatment: NXP900 — This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Mesothelioma
Biomarker criteria
Required: YES1 amplification
YES1 amplification
Required: TYMS amplification
TYMS amplification
Required: FAT1 pathogenic mutation
FAT1 pathogenic mutation
Required: NF2 pathogenic mutation
NF2 pathogenic mutation
Required: LATS1 pathogenic mutation
LATS1 pathogenic gene mutation
Required: YAP1 amplification
YAP1 gene amplification
Required: TAZ1 amplification
TAZ1 gene amplification
Excluded: HER2 overexpression
Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies.
Excluded: BRAF mutation
Subjects with colorectal cancer, glioma, melanoma, or anaplastic thyroid conditions with BRAF mutations.
Excluded: BRAF mutation
Subjects with NSCLC with BRAF...alterations.
Excluded: EGFR alteration
Subjects with NSCLC with EGFR...alterations.
Excluded: HER2 alteration
Subjects with NSCLC with...HER2 alterations.
Excluded: HER2 alteration
Subjects with breast cancer, gastric cancer, esophageal junction adenocarcinoma or biliary cancer with HER2 alterations
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Phoenix, Arizona
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Mayo Clinic · Jacksonville, Florida
- University of Chicago · Chicago, Illinois
- Mayo Clinic Rochester · Rochester, Minnesota
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05873686 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require YES1?
Yes, YES1 amplification is a required biomarker for enrollment.
Does this trial require TYMS?
Yes, TYMS amplification is a required biomarker for enrollment.
Does this trial require FAT1?
Yes, FAT1 pathogenic mutation is a required biomarker for enrollment.
Are patients with HER2 alterations eligible?
No. HER2 overexpression is an exclusion criterion.
Are patients with BRAF alterations eligible?
No. BRAF mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify